Phase 1 study of 9 ING 41, a Glycogen Synthase Kinase 3 Beta (GSK 3ß) inhibitor, as a single agent or with Irinotecan in pediatric patients with refractory malignancies

Gender
Any

Age Group
Any

At a Glance

IRB#IRB20-0855

Lead PhysicianAmi Desai

Collaborator(s)N/A

EligibilityRecruiting